User login
Key clinical point: The combination of apatinib and vinorelbine lowered the risk for disease progression and was well tolerated in patients with metastatic triple-negative breast cancer (TNBC) who had failed first or second-line treatment.
Major finding: There was a significant improvement in progression-free survival with apatinib + vinorelbine vs only vinorelbine (hazard ratio 1.82; P = .026). Leukopenia (42.4% vs 40.6%) and granulocytopenia (57.6% vs 31.3%) were the most frequent grade 3-4 hematologic adverse events in the apatinib + vinorelbine vs vinorelbine group.
Study details: Findings are from the phase 2, NAN study including 66 patients with recurrent or metastatic TNBC who had failed first or second-line treatment and were randomly assigned to receive apatinib + vinorelbine or vinorelbine.
Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Li DD et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: The NAN trial. NPJ Breast Cancer. 2022;8:110 (Sep 20). Doi: 10.1038/s41523-022-00462-6
Key clinical point: The combination of apatinib and vinorelbine lowered the risk for disease progression and was well tolerated in patients with metastatic triple-negative breast cancer (TNBC) who had failed first or second-line treatment.
Major finding: There was a significant improvement in progression-free survival with apatinib + vinorelbine vs only vinorelbine (hazard ratio 1.82; P = .026). Leukopenia (42.4% vs 40.6%) and granulocytopenia (57.6% vs 31.3%) were the most frequent grade 3-4 hematologic adverse events in the apatinib + vinorelbine vs vinorelbine group.
Study details: Findings are from the phase 2, NAN study including 66 patients with recurrent or metastatic TNBC who had failed first or second-line treatment and were randomly assigned to receive apatinib + vinorelbine or vinorelbine.
Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Li DD et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: The NAN trial. NPJ Breast Cancer. 2022;8:110 (Sep 20). Doi: 10.1038/s41523-022-00462-6
Key clinical point: The combination of apatinib and vinorelbine lowered the risk for disease progression and was well tolerated in patients with metastatic triple-negative breast cancer (TNBC) who had failed first or second-line treatment.
Major finding: There was a significant improvement in progression-free survival with apatinib + vinorelbine vs only vinorelbine (hazard ratio 1.82; P = .026). Leukopenia (42.4% vs 40.6%) and granulocytopenia (57.6% vs 31.3%) were the most frequent grade 3-4 hematologic adverse events in the apatinib + vinorelbine vs vinorelbine group.
Study details: Findings are from the phase 2, NAN study including 66 patients with recurrent or metastatic TNBC who had failed first or second-line treatment and were randomly assigned to receive apatinib + vinorelbine or vinorelbine.
Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Li DD et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: The NAN trial. NPJ Breast Cancer. 2022;8:110 (Sep 20). Doi: 10.1038/s41523-022-00462-6